{"product_id":"pcrx-five-forces","title":"(PCRX) Pacira BioSciences, Inc. Porters Five Forces Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eA Must-Have Tool for Decision-Makers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Pacira BioSciences, Inc. Porter's Five Forces Analysis shows the competitive forces affecting the company—rivalry, buyer power, supplier power, substitutes, and new entrants. The page already includes a real preview of the actual report, so you can see the content before buying. Purchase the full version for the complete ready-to-use analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eSuppliers Bargaining Power\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialty API dependence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePacira BioSciences, Inc. depends on specialty APIs like bupivacaine and triamcinolone acetonide, so quality and cGMP compliance matter more than spot price. Suppliers that can meet injectable and liposomal-grade specs can push harder on terms, especially for complex sterile inputs. Pacira reduces that risk with qualified sourcing, long-term ties, and its own formulation know-how.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eContract manufacturing reliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePacira BioSciences depends on specialized contract manufacturing for injectable drugs and device-linked parts, so suppliers with validated capacity can hold real leverage. Because switching vendors means revalidation and quality work, Pacira cannot replace them quickly, which lifts supplier power. \u003c\/p\u003e\n\u003cp\u003eThat leverage is softened by Pacira’s own proprietary standards, but not erased. In FY2025, any tight capacity, lead-time risk, or single-source component issue would still matter more than in a standard pharma supply chain.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory-grade requirements\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSuppliers that meet FDA and quality-system rules are much fewer than in normal industries, so Pacira BioSciences, Inc. has less room to switch vendors. A source change can mean new validation work, audits, and supply delays, which gives compliant suppliers more leverage. That matters more in sterile production, where even one stop can disrupt output and sales.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eProprietary technology insulation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePacira BioSciences, Inc. has supplier power insulation because its MVL drug-delivery know-how is built in-house, so key value is created by its own science, not by commodity inputs. That makes suppliers less able to push price or terms, since the hard-to-copy part is Pacira BioSciences, Inc. technology, not raw materials. In a more commodity-like pharma model, supplier power would be higher.\u003c\/p\u003e\n\u003cp\u003ePacira BioSciences, Inc. still buys inputs, but proprietary formulation expertise shifts more control to the company. That lowers bargaining power versus firms that rely on outsourced, interchangeable manufacturing. If a supplier is replaceable, its leverage stays limited.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOwns critical drug-delivery know-how\u003c\/li\u003e\n\u003cli\u003eLess dependence on outside suppliers\u003c\/li\u003e\n\u003cli\u003eHarder for suppliers to demand premiums\u003c\/li\u003e\n\u003cli\u003eSupplier power stays below commodity pharma\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eInput concentration risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePacira BioSciences, Inc. faces clear input concentration risk: if only a few vendors supply key excipients, packaging, or device parts, those suppliers can gain pricing and allocation power. That matters because any shortage can disrupt production of EXPAREL, ZILRETTA, or iovera, even though the products are differentiated. In 2024, EXPAREL was still Pacira BioSciences, Inc.'s main revenue driver, so one weak link in the supply chain can hit output fast.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFew qualified suppliers raise bargaining power.\u003c\/li\u003e\n\u003cli\u003eShortages can halt EXPAREL, ZILRETTA, iovera.\u003c\/li\u003e\n\u003cli\u003eCore product reliance amplifies risk.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePacira’s Supplier Power Is Moderate Despite High Switching Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePacira BioSciences, Inc. faces moderate supplier power: sterile, FDA-compliant inputs and validated contract manufacturers are hard to replace, so switching costs stay high. That said, Pacira BioSciences, Inc.'s proprietary formulation know-how and qualified sourcing narrow supplier leverage versus commodity pharma.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eDriver\u003c\/th\u003e\n\u003cth\u003eEffect\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eValidated sterile inputs\u003c\/td\u003e\n\u003ctd\u003eRaises supplier power\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSwitching\/revalidation\u003c\/td\u003e\n\u003ctd\u003eLimits vendor replacement\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIn-house know-how\u003c\/td\u003e\n\u003ctd\u003eReduces leverage\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eTailored for Pacira BioSciences, Inc., this analysis gauges competitive pressure, buyer power, supplier leverage, and substitution threats.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eQuickly spot Pacira BioSciences’ competitive pressures—so you can cut uncertainty and make faster, smarter strategy calls.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a traceable source trail for Pacira BioSciences data, boosting credibility and helping decision-makers verify assumptions fast.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCustomers Bargaining Power\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHospital purchasing groups\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHospital purchasing groups give Pacira BioSciences, Inc. customers strong leverage because they buy for hospitals, surgery centers, and health systems in bulk. Large group purchasing organizations can press on price, rebates, and formulary access, and Pacira still relied on a concentrated U.S. institutional channel in 2025, with 2025 net product sales of about $617 million. That scale makes switching easier for buyers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical adoption hurdles\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eClinical adoption is a real hurdle for Pacira BioSciences, Inc. because physicians and anesthesiology teams only expand use when they see clear gains in pain control, safety, and workflow. If the data are not strong enough, they can limit EXPAREL to select cases or delay adoption, which keeps bargaining power with customers. Demand depends on clinical confidence, not just product availability.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReimbursement sensitivity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePacira BioSciences, Inc. faces high customer bargaining power because reimbursement can speed or slow adoption of non-opioid pain care. In 2025, CMS raised hospital outpatient payment rates 2.9%, but hospitals still judge total episode cost, not just drug price, so they press for discounts when coverage is tight. That makes value proof and economic data key. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSwitching alternatives\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePacira BioSciences faces high buyer power because surgeons and hospitals can switch across regional anesthetics, steroids, nerve blocks, and opioid-based pain protocols. If a Pacira product does not match a procedure, formulary, or budget, buyers can move to a lower-cost substitute fast. That choice pressure keeps pricing and mix discipline tight.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMany therapy classes compete head-to-head.\u003c\/li\u003e\n\u003cli\u003eProcedure fit drives switching.\u003c\/li\u003e\n\u003cli\u003eBudget limits strengthen buyer leverage.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eConcentrated end users\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePacira BioSciences, Inc. faces high customer bargaining power because its end users are concentrated in hospitals, health systems, and ambulatory surgery centers, not fragmented consumers. These buyers use procurement teams and formal budgets, so they can push back on price and contract terms. That means Pacira has to prove clear clinical and economic value to defend pricing power.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBuyers are large institutional accounts\u003c\/li\u003e\n\u003cli\u003eProcurement teams increase price pressure\u003c\/li\u003e\n\u003cli\u003eValue proof protects Pacira’s margins\u003c\/li\u003e\n\u003cli\u003eContract leverage is stronger in 2025-2026\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePacira Faces Heavy Buyer Pressure as Large Health Systems Push Prices\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePacira BioSciences, Inc. faces high customer bargaining power because 2025 net product sales were about $617 million and sales run through large hospital, health system, and ASC buyers. Those accounts use GPOs and procurement teams to push on price, rebates, and formulary access. Switching pressure stays high because buyers can compare EXPAREL with lower-cost pain protocols.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eDriver\u003c\/th\u003e\n\u003cth\u003e2025 data\u003c\/th\u003e\n\u003cth\u003eEffect\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet product sales\u003c\/td\u003e\n\u003ctd\u003e$617 million\u003c\/td\u003e\n\u003ctd\u003eBuyer concentration\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCMS hospital outpatient rates\u003c\/td\u003e\n\u003ctd\u003e+2.9%\u003c\/td\u003e\n\u003ctd\u003ePrice pressure stays tight\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003ePacira BioSciences, Inc. Porter's Five Forces Analysis\u003c\/h2\u003e\n\u003cp\u003eThis preview shows the exact Pacira BioSciences, Inc. Porter's Five Forces Analysis you'll receive immediately after purchase—no surprises, no placeholders. The document displayed here is the same professionally written file you’ll download, fully formatted and ready to use. What you’re seeing is the final version, so you can buy with confidence and get instant access to this exact analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Rivalry-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eRivalry Among Competitors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePain management competition\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePacira BioSciences, Inc. faces intense pain-management rivalry from pharmaceuticals, regional anesthesia products, and device-based options. EXPAREL is approved for up to 72 hours of postsurgical pain control, but many rivals sell lower-cost legacy drugs and broad portfolios, so buyers compare clinical benefit, total cost, and ease of use. That keeps pricing pressure high and switching easy.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBrand and evidence competition\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEXPAREL and ZILRETTA depend on differentiated clinical data, real-world use, and physician familiarity to defend share. When rivals publish stronger outcomes or win formulary access, Pacira can lose pricing power and prescriptions. That keeps brand and evidence competition intense, with constant pressure to prove better pain control and recovery results.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Rivalry-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOpioid alternative positioning\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePacira BioSciences, Inc. competes on non-opioid pain control, but that edge is narrowing as rivals push opioid-sparing and multimodal regimens without Pacira’s same drug-delivery tech. The fight is for the same hospital buyer, where lower readmissions and faster discharge matter more than brand alone. As more firms target this value proposition, competitive rivalry keeps rising. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eDevice and drug overlap\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePacira BioSciences, Inc.’s iovera system sits in a crowded pain-care market, so it competes with devices, drugs, and procedure-based options at the same time. That overlap raises rivalry because rivals can win the same patient with a shot, a device, or an operating-room approach, not just one class of product. In the U.S., about 51.6 million adults live with chronic pain, so the fight for treatment share is wide.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCompetes across drug and device lines.\u003c\/li\u003e\n\u003cli\u003eSubstitutes include meds and procedures.\u003c\/li\u003e\n\u003cli\u003eBroad overlap makes rivalry harder to avoid.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePricing and access pressure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHospitals and payers keep pressure on Pacira BioSciences, Inc. to prove that premium pricing delivers measurable outcomes, not just brand strength. If a rival offers similar pain relief at a lower cost, Pacira may need discounts or contract concessions, which keeps competitive rivalry high even for differentiated products.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOutcome proof drives pricing power.\u003c\/li\u003e\n\u003cli\u003eLower-cost rivals force concessions.\u003c\/li\u003e\n\u003cli\u003eRivalry stays high despite differentiation.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePacira Faces Fierce Hospital Pain Care Competition\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCompetitive rivalry is high because Pacira BioSciences, Inc. sells into crowded hospital pain care, where drugs, devices, and procedures all compete for the same patient. In 2025, EXPAREL and ZILRETTA still relied on clinical proof and formulary access to defend share, but lower-cost opioid-sparing rivals kept pricing pressure intense.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2025\/2026 signal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eEXPAREL duration\u003c\/td\u003e\n\u003ctd\u003eUp to 72 hours\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. chronic pain adults\u003c\/td\u003e\n\u003ctd\u003eAbout 51.6 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCore rivalry drivers\u003c\/td\u003e\n\u003ctd\u003ePrice, outcomes, access\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eSubstitutes Threaten\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeneric analgesics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGeneric opioids, NSAIDs, and local anesthetics are strong substitutes for Pacira BioSciences, Inc.’s pain therapies because they are familiar, widely available, and usually far cheaper. In many procedures, buyers compare them against Pacira BioSciences, Inc. products on total cost, and the lower upfront price often wins. That keeps switching pressure high, especially in routine cases where clinical differentiation is smaller.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegional anesthesia techniques\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRegional anesthesia techniques, especially peripheral nerve blocks and epidurals, can replace or reduce Pacira solutions when anesthesiologists already use standard protocols. These methods deliver targeted pain control and can cover the first 12 to 24 hours after surgery, so many hospitals can use them without adding a new product. That keeps the substitute threat strong for Pacira BioSciences, Inc.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Substitutes-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMultimodal pain protocols\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHospitals often use multimodal pain pathways, mixing acetaminophen, NSAIDs, nerve blocks, and non-drug care, so if the bundle controls pain well, demand for Pacira BioSciences, Inc. branded injectable EXPAREL can slip. That makes substitution easier because the buyer swaps a full protocol, not just one drug. In 2025, this pressure stayed high as hospitals kept pushing lower-cost, opioid-sparing care.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eOpioid-based regimens\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOpioid-based regimens still act as a fallback for acute pain, with U.S. opioid prescriptions near 125 million in 2023, so entrenched use remains hard to displace. When cost or access matters more than opioid avoidance, hospitals can choose cheap generics over Pacira BioSciences, Inc. products. That keeps the threat of substitutes high, especially in fast-moving surgical settings.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCheap, familiar, widely stocked fallback\u003c\/li\u003e\n\u003cli\u003ePrice and access often beat avoidance\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eProcedure-level alternatives\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eProcedure-level alternatives are a real substitute threat for Pacira BioSciences, Inc. When surgeons use less invasive techniques, enhanced recovery pathways, or shorter-length-of-stay protocols, post-op pain can be managed with fewer drug doses, so Pacira BioSciences, Inc. may see lower use of EXPAREL and other products.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBetter care pathways can replace drug need.\u003c\/li\u003e\n\u003cli\u003eShorter stays cut post-op pain product use.\u003c\/li\u003e\n\u003cli\u003eProcess redesign can lower Pacira BioSciences, Inc. demand.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePacira Faces Strong, Low-Cost Pain Relief Alternatives\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSubstitutes stay strong for Pacira BioSciences, Inc.: cheap generics, nerve blocks, and multimodal pain bundles often beat EXPAREL on price and workflow. U.S. opioid prescriptions were near 125 million in 2023, so low-cost fallback use remains deep. Shorter stays and less invasive surgery also cut need for Pacira BioSciences, Inc. pain drugs.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSubstitute\u003c\/th\u003e\n\u003cth\u003eKey data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eOpioids\u003c\/td\u003e\n\u003ctd\u003e~125M U.S. Rx, 2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNerve blocks\u003c\/td\u003e\n\u003ctd\u003e12-24h coverage\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMultimodal care\u003c\/td\u003e\n\u003ctd\u003eLower drug use\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Entrants-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eEntrants Threaten\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh regulatory barriers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHigh regulatory barriers keep the threat of new entrants low for Pacira BioSciences, Inc. Injectable pain therapies need FDA review, clinical proof, and manufacturing validation, and late-stage trials can cost tens of millions of dollars and take years. That delay and cash burn make fast entry unlikely, so only well-funded rivals can try.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatent and know-how protection\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePacira BioSciences, Inc. leans on proprietary formulations and drug-delivery know-how, so a rival would need more than a similar recipe to compete. Even if a copycat product is made, matching Exparel’s release profile, stability, and manufacturing consistency is hard and costly. That IP and process gap keeps the threat from immediate new entrants low, especially while Pacira still depends on patent-backed franchise value.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Entrants-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCapital intensive launch\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePacira BioSciences, Inc. shows why entry is hard: a specialty drug launch can need $50M to $200M+ in R\u0026amp;D, trials, quality systems, and scale-up before revenue starts. New players also need hospital sales teams and reimbursement support, which can take 6-18 months per health system. That capex-heavy path makes this far tougher than many other healthcare niches.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eDistribution and adoption hurdles\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHospitals and clinicians do not switch pain therapies quickly; they want published evidence, safety data, and a long track record before changing practice. A new entrant must clear formulary review, procurement checks, and physician trust, which can take many months and raise launch costs. That slows adoption and gives Pacira BioSciences, Inc. a real barrier against fast followers.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFormulary approval slows hospital entry.\u003c\/li\u003e\n\u003cli\u003eProcurement teams block weak evidence.\u003c\/li\u003e\n\u003cli\u003ePhysician trust takes time to earn.\u003c\/li\u003e\n\u003cli\u003eAdoption friction protects incumbents.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSpecialized manufacturing barrier\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePacira BioSciences, Inc. faces a specialized manufacturing barrier because sterile injectables and device-enabled pain products need validated aseptic lines, tight quality control, and FDA-ready documentation. A single production failure can delay launch or trigger recalls, which is especially costly when one batch can affect the full supply chain. That keeps the threat of new entrants moderate, not high.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cp\u003eNeeds sterile, validated facilities\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eQuality failures can trigger recalls\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eHigh capex and expertise deter small entrants\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eBarrier keeps entry risk moderate\u003c\/p\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLow Threat of New Entrants Protects Pacira’s Market Position\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThreat of new entrants for Pacira BioSciences, Inc. stays low. FDA review, sterile-injectable manufacturing, and hospital formulary access raise the bar, while specialty drug launches can need $50M to $200M+ before revenue. Exparel’s IP and channel depth make fast entry unlikely, so only well-funded rivals can try.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eBarrier\u003c\/th\u003e\n\u003cth\u003eImpact\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFDA and trials\u003c\/td\u003e\n\u003ctd\u003eYears, high cash burn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing\u003c\/td\u003e\n\u003ctd\u003eValidated sterile lines\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospital access\u003c\/td\u003e\n\u003ctd\u003eSlow formulary approval\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234878628105,"sku":"pcrx-five-forces","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/pcrx-five-forces.webp?v=1785728286","url":"https:\/\/dcfanalyst.com\/products\/pcrx-five-forces","provider":"DCF Analyst","version":"1.0","type":"link"}